Advertisement
Screener

Spero Therapeutics, Inc. (SPRO) Stock Issued During Period, Value, Stock Options Exercised

Spero Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • Spero Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-12-31 was $1.00K, a 99.57% decline year-over-year.
  • Spero Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
  • Spero Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-06-30 was $231.00K, a 16.61% decline year-over-year.
  • Spero Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-03-31 was $188.00K, a 102.15% increase year-over-year.
  • Spero Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $420.00K, a 71.03% decline from fiscal 2021.
  • Spero Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.45M, a 33.76% decline from fiscal 2020.
  • Spero Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $2.19M, a 330.91% increase from fiscal 2019.
  • Spero Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $508.00K, a 51.64% increase from fiscal 2018.
Period endStock Issued During Period, Value, Stock Options Exercised 3 monthStock Issued During Period, Value, Stock Options Exercised 12 month
2022-12-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13
$420.00K
10-K · filed 2024-03-13
2022-09-30$0.00
10-Q · filed 2023-11-13
$651.00K
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$231.00K
10-Q · filed 2023-08-10
$1.48M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$188.00K
10-Q · filed 2023-05-11
$1.52M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$232.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
$1.45M
10-K · filed 2023-03-30
2021-09-30$826.00K
10-Q · filed 2022-11-14
$2.38M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$277.00K
10-Q · filed 2022-08-10
$1.75M
derived: sum of 4 quarters · filed 2022-08-10
2021-03-31$93.00K
10-Q · filed 2022-05-16
$1.74M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$1.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$2.19M
10-K · filed 2022-03-31
2020-09-30$201.00K
10-Q · filed 2021-11-10
$1.11M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$269.00K
10-Q · filed 2021-08-05
$957.00K
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$539.00K
10-Q · filed 2021-05-06
$988.00K
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31$98.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
$508.00K
10-K · filed 2021-03-11
2019-09-30$51.00K
10-Q · filed 2020-11-05
$548.00K
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$300.00K
10-Q · filed 2020-08-06
$643.00K
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31$59.00K
10-Q · filed 2020-05-08
$394.00K
derived: sum of 4 quarters · filed 2020-05-08
2018-12-31$138.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
$335.00K
10-K · filed 2020-03-16
2018-09-30$146.00K
10-Q · filed 2019-11-04
2018-06-30$51.00K
10-Q · filed 2019-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cingulate Inc. (CING)United States$0.073B-2.64
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
Yarrow Bioscience, Inc. (YARW)United States$0.070B
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17